$EQ
Equillium Inc

2022 Q1 Form 10-K Financial Statement

#000095017022004407 Filed on March 23, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.517M $2.838M $11.41M
YoY Change 20.45% 18.25% 12.27%
% of Gross Profit
Research & Development $10.76M $7.549M $26.38M
YoY Change 83.04% 5.29% 36.09%
% of Gross Profit
Depreciation & Amortization $25.00K $19.00K $72.00K
YoY Change 25.0% -5.0% 60.0%
% of Gross Profit
Operating Expenses $37.33M $10.39M $37.79M
YoY Change 329.32% 15.8% 27.88%
Operating Profit -$37.33M -$37.79M
YoY Change 329.32% 27.88%
Interest Expense -$230.0K -$256.0K -$1.016M
YoY Change -8.0% 16.36% 63.87%
% of Operating Profit
Other Income/Expense, Net -$88.00K $22.00K -$1.266M
YoY Change -70.27% -92.14% 377.74%
Pretax Income -$37.42M -$10.62M -$39.05M
YoY Change 316.21% 19.07% 30.99%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$37.42M -$10.62M -$39.05M
YoY Change 316.16% 19.1% 30.99%
Net Earnings / Revenue
Basic Earnings Per Share -$1.17 -$1.36
Diluted Earnings Per Share -$1.174M -$361.0K -$1.356M
COMMON SHARES
Basic Shares Outstanding 34.28M 29.39M 28.81M
Diluted Shares Outstanding 31.87M 28.81M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $68.82M $80.71M $80.71M
YoY Change -33.87% -1.77% -1.76%
Cash & Equivalents $26.24M $50.37M $50.37M
Short-Term Investments $42.58M $30.35M $30.35M
Other Short-Term Assets $3.262M $2.659M $2.659M
YoY Change 30.48% -11.37% -11.66%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $72.09M $83.37M $83.37M
YoY Change -32.39% -2.12% -2.11%
LONG-TERM ASSETS
Property, Plant & Equipment $464.0K $237.0K $1.882M
YoY Change 108.07% -0.84% 684.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $145.0K $153.0K $153.0K
YoY Change 920.0% 665.0%
Total Long-Term Assets $2.150M $2.035M $2.035M
YoY Change 864.13% 701.18% 682.69%
TOTAL ASSETS
Total Short-Term Assets $72.09M $83.37M $83.37M
Total Long-Term Assets $2.150M $2.035M $2.035M
Total Assets $74.24M $85.41M $85.41M
YoY Change -30.52% -0.03% -0.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.210M $1.225M $1.225M
YoY Change 81.15% -55.71% -55.78%
Accrued Expenses $5.626M $5.886M $6.262M
YoY Change 116.97% 109.24% 122.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.857M $1.428M $1.428M
YoY Change 14.28% -14.29% -14.49%
Total Short-Term Liabilities $13.11M $8.915M $8.915M
YoY Change 76.8% 23.05% 22.97%
LONG-TERM LIABILITIES
Long-Term Debt $7.370M $8.750M $8.750M
YoY Change -1.81% 5.74% 5.68%
Other Long-Term Liabilities $1.122M $1.235M $1.235M
YoY Change 3105.71% 2187.04% 2370.0%
Total Long-Term Liabilities $7.370M $8.750M $9.985M
YoY Change -2.27% 5.05% 19.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.11M $8.915M $8.915M
Total Long-Term Liabilities $7.370M $8.750M $9.985M
Total Liabilities $21.61M $18.90M $18.90M
YoY Change 44.44% 21.36% 21.39%
SHAREHOLDERS EQUITY
Retained Earnings -$147.4M -$110.0M
YoY Change 84.44% 55.06%
Common Stock $200.5M $176.6M
YoY Change 16.52% 25.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $52.63M $66.51M $66.50M
YoY Change
Total Liabilities & Shareholders Equity $74.24M $85.41M $85.41M
YoY Change -30.52% -0.03% -0.03%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$37.42M -$10.62M -$39.05M
YoY Change 316.16% 19.1% 30.99%
Depreciation, Depletion And Amortization $25.00K $19.00K $72.00K
YoY Change 25.0% -5.0% 60.0%
Cash From Operating Activities -$12.13M -$10.13M -$32.08M
YoY Change 52.74% 22.82% 30.28%
INVESTING ACTIVITIES
Capital Expenditures $223.0K $0.00 $57.00K
YoY Change -100.0% -71.78%
Acquisitions
YoY Change
Other Investing Activities -$11.76M -$16.89M $27.46M
YoY Change -342.02% -0.71% -249.34%
Cash From Investing Activities -$11.99M -$16.89M $27.41M
YoY Change -346.6% -0.83% -247.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 225.0K 31.06M
YoY Change -100.0% 1025.0% -42.42%
NET CHANGE
Cash From Operating Activities -12.13M -10.13M -32.08M
Cash From Investing Activities -11.99M -16.89M 27.41M
Cash From Financing Activities 0.000 225.0K 31.06M
Net Change In Cash -24.12M -26.80M 26.38M
YoY Change -189.74% 6.08% 145.14%
FREE CASH FLOW
Cash From Operating Activities -$12.13M -$10.13M -$32.08M
Capital Expenditures $223.0K $0.00 $57.00K
Free Cash Flow -$12.36M -$10.13M -$32.14M
YoY Change 55.55% 23.27% 29.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001746466
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-38692
CY2021 dei Entity Registrant Name
EntityRegistrantName
EQUILLIUM, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1554746
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
2223 Avenida de la Playa
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 105
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
CY2021 dei City Area Code
CityAreaCode
858
CY2021 dei Local Phone Number
LocalPhoneNumber
412-5302
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
EQ
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
95300000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34275898
CY2021 dei Auditor Firm
AuditorFirmId
185
CY2021 dei Auditor Name
AuditorName
KPMG LLP
CY2021 dei Auditor Location
AuditorLocation
San Diego, California, United States
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50366000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23982000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
30345000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
58181000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2659000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3011000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
83370000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
85174000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1645000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
237000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
239000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
153000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2021Q4 us-gaap Assets
Assets
85405000
CY2020Q4 us-gaap Assets
Assets
85428000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1225000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2766000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5886000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2813000
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1428000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1666000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
376000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8915000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7245000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8750000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8275000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1235000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
54000
CY2021Q4 us-gaap Liabilities
Liabilities
18900000
CY2020Q4 us-gaap Liabilities
Liabilities
15574000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29455668
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29455668
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24753102
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24753102
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
176618000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
141074000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-297000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109977000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70925000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
66505000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
69854000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85405000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85428000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26379000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19384000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11407000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10164000
CY2021 us-gaap Operating Expenses
OperatingExpenses
37786000
CY2020 us-gaap Operating Expenses
OperatingExpenses
29548000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-37786000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-29548000
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
1073000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
1099000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
57000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
476000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-250000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
358000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1266000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-265000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-39052000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-29813000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-59000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-41000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
218000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-277000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
159000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-318000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38893000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30131000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.36
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.46
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28806310
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20355534
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
41848000
CY2020 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
35717000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
252000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
156000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
73000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3817000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-318000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-29813000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
69854000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
891000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
261000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
73000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4410000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
159000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-39052000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
66505000
CY2021 us-gaap Profit Loss
ProfitLoss
-39052000
CY2020 us-gaap Profit Loss
ProfitLoss
-29813000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
72000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
45000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4410000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3817000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-240000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
360000
CY2020 eq Non Cash Consulting Expense
NonCashConsultingExpense
81000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
237000
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
260000
CY2020 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
13000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-314000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-104000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-214000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
491000
CY2021 eq Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-114000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1578000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
894000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3099000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
852000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-151000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32081000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24624000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
57000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
202000
CY2021 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
32992000
CY2020 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
55510000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
60455000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
37120000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27406000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18592000
CY2021 eq Proceeds From Registered Direct Offering Net Of Offering Costs
ProceedsFromRegisteredDirectOfferingNetOfOfferingCosts
29909000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
891000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
261000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
156000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31061000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53945000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
26384000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10763000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23982000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13219000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50366000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23982000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
836000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
839000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1759000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
14000
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-03-16
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
80700000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
200000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-300000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company’s consolidated financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. Significant estimates in the Company’s consolidated financial statements relate to accrued research and development expense and the valuation of equity awards. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company’s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk and Off-Balance Sheet Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company’s investment policy includes guidelines for the quality of the related institutions and financial instruments and defines allowable investments that the Company may invest in, which the Company believes minimizes the exposure to concentration of credit risk.</span></p>
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
30397000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
52000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
30345000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
58173000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
58181000
CY2021 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2021 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0
CY2020 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
13000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5313166
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2543745
CY2021Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
30345000
CY2020Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
58181000
CY2021Q4 us-gaap Notes Payable
NotesPayable
10200000
CY2020Q4 us-gaap Notes Payable
NotesPayable
9900000
CY2021Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2020Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
147000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
74000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
237000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
239000
CY2021 us-gaap Depreciation
Depreciation
72000
CY2020 us-gaap Depreciation
Depreciation
45000
CY2021 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2020 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1645000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
376000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1235000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1611000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M10D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
220000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1759000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
510000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
494000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
492000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
192000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
169000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
28000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1885000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
274000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1611000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
510000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
494000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
492000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
192000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
169000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
28000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1885000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
71000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
71000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5886000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2813000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2511000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1870000
CY2021Q4 eq Accrued Clinical Studies
AccruedClinicalStudies
2627000
CY2020Q4 eq Accrued Clinical Studies
AccruedClinicalStudies
493000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
245000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
307000
CY2021Q4 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
432000
CY2020Q4 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
72000
CY2019Q3 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2024-06-01
CY2019Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
300000
CY2021Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Next Twelve Months
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1428000
CY2021Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Two
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearTwo
5714000
CY2021Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Three
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearThree
3358000
CY2021Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFee
10500000
CY2021Q4 eq Unaccreted Liability For Final Payment Fee
UnaccretedLiabilityForFinalPaymentFee
190000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
132000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
10178000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1428000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8750000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29455668
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24753102
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
9000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
900000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3000000.0
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4100000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.94
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.11
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9200000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4410000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3817000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0068
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0065
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8855
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8956
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M7D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 eq Dividends Paid On Common Stock
DividendsPaidOnCommonStock
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
900000
CY2021 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29813000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6549848
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4195805
CY2021 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000
CY2020 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000
CY2021Q4 eq Area Of Office Space Leased
AreaOfOfficeSpaceLeased
4727
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-37705000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-29420000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1347000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-393000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39052000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020 eq Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
15000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8201000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6261000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
6000
CY2021 eq Income Tax Reconciliation Federal Research And Orphan Drug Credits
IncomeTaxReconciliationFederalResearchAndOrphanDrugCredits
1713000
CY2020 eq Income Tax Reconciliation Federal Research And Orphan Drug Credits
IncomeTaxReconciliationFederalResearchAndOrphanDrugCredits
445000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
387000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
451000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
97000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 eq Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
31000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
346000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
41000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
72000
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
367000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9360000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6227000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19344000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12338000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3940000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1940000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
108000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
118000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
1134000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
888000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1076000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
286000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25602000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15570000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25215000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15564000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
387000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
6000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25200000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9700000
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
85500000
CY2021 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
Federal net operating losses generated after December 31, 2017 carryover indefinitely but the deductibility of such federal net operating losses in taxable years beginning after December 31, 2020 is limited to 80% of taxable income.
CY2021 eq Operating Loss Carryforwards Expiration Year
OperatingLossCarryforwardsExpirationYear
2037
CY2021 eq Tax Credit Carryforward Expiration Year
TaxCreditCarryforwardExpirationYear
2037
CY2021 eq Cumulative Change In Ownership Percentage
CumulativeChangeInOwnershipPercentage
0.50
CY2021 eq Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2667000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
360000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
2266000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1988000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
554000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
319000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5487000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2667000
CY2021 eq Carryback Period Of Certain Losses Period
CarrybackPeriodOfCertainLossesPeriod
P5Y
CY2020 eq Suspension Of Limitation Imposed By Tax Cuts And Jobs Act Percent
SuspensionOfLimitationImposedByTaxCutsAndJobsActPercent
0.80
CY2019 eq Suspension Of Limitation Imposed By Tax Cuts And Jobs Act Percent
SuspensionOfLimitationImposedByTaxCutsAndJobsActPercent
0.80
CY2018 eq Suspension Of Limitation Imposed By Tax Cuts And Jobs Act Percent
SuspensionOfLimitationImposedByTaxCutsAndJobsActPercent
0.80
CY2021 eq Research And Experimental Expenditures Capitalized Cost Amortization Period
ResearchAndExperimentalExpendituresCapitalizedCostAmortizationPeriod
P5Y
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0

Files In Submission

Name View Source Status
0000950170-22-004407-index-headers.html Edgar Link pending
0000950170-22-004407-index.html Edgar Link pending
0000950170-22-004407.txt Edgar Link pending
0000950170-22-004407-xbrl.zip Edgar Link pending
eq-20211231.htm Edgar Link pending
eq-20211231.xsd Edgar Link pending
eq-20211231_cal.xml Edgar Link unprocessable
eq-20211231_def.xml Edgar Link unprocessable
eq-20211231_htm.xml Edgar Link completed
eq-20211231_lab.xml Edgar Link unprocessable
eq-20211231_pre.xml Edgar Link unprocessable
eq-ex10_23.htm Edgar Link pending
eq-ex10_25.htm Edgar Link pending
eq-ex10_28.htm Edgar Link pending
eq-ex10_29.htm Edgar Link pending
eq-ex21_1.htm Edgar Link pending
eq-ex23_1.htm Edgar Link pending
eq-ex31_1.htm Edgar Link pending
eq-ex31_2.htm Edgar Link pending
eq-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img267300541_0.jpg Edgar Link pending
img267300541_1.jpg Edgar Link pending
img267300541_10.jpg Edgar Link pending
img267300541_11.jpg Edgar Link pending
img267300541_12.jpg Edgar Link pending
img267300541_2.jpg Edgar Link pending
img267300541_3.jpg Edgar Link pending
img267300541_4.jpg Edgar Link pending
img267300541_5.jpg Edgar Link pending
img267300541_6.jpg Edgar Link pending
img267300541_7.jpg Edgar Link pending
img267300541_8.jpg Edgar Link pending
img267300541_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending